QURE News

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V. (QURE) - Contact Kessler Topaz Meltzer & Check, LLP

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against uniQure N.V.

uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QURE

UNIQURE N.V. (QURE) INVESTOR ALERT Investors With Large Losses in uniQure N.V. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

QURE STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Advises of Securities Class Action Against uniQure N.V. – QURE

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm